SMi has developed a technology that directly visualises and counts infectious particles to provide accurate diagnosis at unprecedented speeds. The same technology can be used to directly measure individual drug interactions, dramatically cutting costs and speeding drug development. This has never been done before.
SMi’s automated, high resolution optical technology is capable of viewing single molecule interactions in real time. It is the first optical technology to achieve such a high spatial (1.6nm) and temporal (500 μs) resolution.
Using this significant advancement in optical technology, SMi is developing a range of intelligent instruments including:
• A diagnostic device capable of detecting disease within the first 24 hours of infection and able to distinguish between numerous diseases simultaneously. This high performance device can process hundreds of patient samples in just a few minutes.
• A super resolution microscope that allows scientists to determine key components of drug-receptor interactions, such as the number, position, and rate constants of individual molecules.
|Aim of funding||Growth|
|HMRC Advanced Assurance received||Yes|
|Envisaged investor exit||IPO or Trade Sale|
|Targeted return||3-5x Capital Invested|